Compare Stocks: ABVC, RFL, VANI, and AARD

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AARD Aardvark Therapeutics	$5.38 -2.7%	$6.24	$3.35 ▼ $17.94	$117.74M	3.74	134,806 shs	129,809 shs
ABVC ABVC BioPharma	$1.16 +0.9%	$1.02	$0.71 ▼ $3.40	$30.92M	0.61	121,097 shs	199,552 shs
RFL Rafael	$2.06 -0.1%	$2.19	$1.12 ▼ $3.96	$106.60M	0.4	112,748 shs	361,465 shs
VANI Vivani Medical	$1.19 -1.7%	$1.36	$0.92 ▼ $1.92	$107.34M	2.36	208,693 shs	904,413 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AARD Aardvark Therapeutics	0.00%	+4.87%	-8.66%	+36.58%	-50.96%
ABVC ABVC BioPharma	0.00%	+18.36%	+30.35%	-14.07%	-59.44%
RFL Rafael	0.00%	-10.76%	+8.61%	-25.98%	+47.99%
VANI Vivani Medical	0.00%	-6.30%	-15.60%	+3.48%	-17.93%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AARD Aardvark Therapeutics	$5.38 -2.7%	$6.24	$3.35 ▼ $17.94	$117.74M	3.74	134,806 shs	129,809 shs
ABVC ABVC BioPharma	$1.16 +0.9%	$1.02	$0.71 ▼ $3.40	$30.92M	0.61	121,097 shs	199,552 shs
RFL Rafael	$2.06 -0.1%	$2.19	$1.12 ▼ $3.96	$106.60M	0.4	112,748 shs	361,465 shs
VANI Vivani Medical	$1.19 -1.7%	$1.36	$0.92 ▼ $1.92	$107.34M	2.36	208,693 shs	904,413 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AARD Aardvark Therapeutics	0.00%	+4.87%	-8.66%	+36.58%	-50.96%
ABVC ABVC BioPharma	0.00%	+18.36%	+30.35%	-14.07%	-59.44%
RFL Rafael	0.00%	-10.76%	+8.61%	-25.98%	+47.99%
VANI Vivani Medical	0.00%	-6.30%	-15.60%	+3.48%	-17.93%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AARD Aardvark Therapeutics	2.42	Hold	$15.33	185.01% Upside
ABVC ABVC BioPharma	1.00	Sell	N/A	N/A
RFL Rafael	1.00	Sell	N/A	N/A
VANI Vivani Medical	2.25	Hold	$3.75	215.13% Upside

Current Analyst Ratings Breakdown

Latest ABVC, RFL, VANI, and AARD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/11/2026	ABVC ABVC BioPharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/25/2026	RFL Rafael	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/20/2026	AARD Aardvark Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$6.00
7/7/2026	VANI Vivani Medical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/2/2026	AARD Aardvark Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/23/2026	VANI Vivani Medical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/23/2026	VANI Vivani Medical	Lake Street Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$4.00
6/23/2026	VANI Vivani Medical	Lake Street Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$4.00

(Data available from 9/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AARD Aardvark Therapeutics	N/A	N/A	N/A	N/A	$4.90 per share	N/A
ABVC ABVC BioPharma	$510K	60.62	N/A	N/A	$0.52 per share	2.23
RFL Rafael	$920K	116.27	N/A	N/A	$1.91 per share	1.08
VANI Vivani Medical	N/A	N/A	N/A	N/A	$0.20 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AARD Aardvark Therapeutics	-$57.59M	-$3.21	N/A	N/A	N/A	N/A	-71.54%	-64.94%	N/A
ABVC ABVC BioPharma	-$7.91M	-$0.30	N/A	N/A	N/A	N/A	-47.68%	-30.97%	11/16/2026 (Estimated)
RFL Rafael	-$30.52M	-$0.68	N/A	N/A	N/A	-3,321.74%	-41.27%	-35.32%	10/28/2026 (Estimated)
VANI Vivani Medical	-$26.61M	-$0.35	N/A	N/A	N/A	N/A	-191.05%	-70.91%	11/12/2026 (Estimated)

Latest ABVC, RFL, VANI, and AARD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	VANI Vivani Medical	-$0.0833	-$0.07	+$0.0133	-$0.07	N/A	N/A
8/12/2026	Q2 2026	ABVC ABVC BioPharma	-$0.40	-$0.03	+$0.37	-$0.03	$0.11 million	N/A
8/11/2026	Q2 2026	AARD Aardvark Therapeutics	-$0.87	-$0.66	+$0.21	-$0.66	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AARD Aardvark Therapeutics	N/A	N/A	N/A	N/A	N/A
ABVC ABVC BioPharma	N/A	N/A	N/A	N/A	N/A
RFL Rafael	N/A	N/A	N/A	N/A	N/A
VANI Vivani Medical	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AARD Aardvark Therapeutics	N/A	12.63	12.63
ABVC ABVC BioPharma	N/A	0.07	0.07
RFL Rafael	N/A	3.16	3.14
VANI Vivani Medical	N/A	3.25	3.25

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AARD Aardvark Therapeutics	N/A
ABVC ABVC BioPharma	11.38%
RFL Rafael	11.30%
VANI Vivani Medical	6.78%

Insider Ownership

Company	Insider Ownership
AARD Aardvark Therapeutics	17.80%
ABVC ABVC BioPharma	19.00%
RFL Rafael	32.90%
VANI Vivani Medical	53.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AARD Aardvark Therapeutics	28	21.88 million	17.99 million	N/A
ABVC ABVC BioPharma	19	26.65 million	21.59 million	Not Optionable
RFL Rafael	23	52.00 million	34.89 million	Optionable
VANI Vivani Medical	36	90.20 million	42.13 million	Optionable

ABVC, RFL, VANI, and AARD Headlines

Recent News About These Companies

Vivani Medical Announces Merger Deal Involving Cortigent

September 16, 2026 | tipranks.com

Vivani Medical (NASDAQ:VANI) Trading Down 9.1% - Time to Sell?

September 9, 2026 | americanbankingnews.com

Vivani Medical (NASDAQ:VANI) Trading Down 9.1% - Here's What Happened

September 9, 2026 | marketbeat.com

Vivani Medical to Participate in Upcoming Lake Street and H.C. Wainwright Investor Conferences

September 3, 2026 | quiverquant.comQ

Vivani Medical Announces Participation in Upcoming Investor Conferences

September 3, 2026 | globenewswire.com

Analysts Offer Insights on Healthcare Companies: Vivani Medical (VANI) and InspireMD (NSPR)

August 20, 2026 | theglobeandmail.com

Vivani Medical Inc U5P

August 19, 2026 | morningstar.comM

Vivani Medical Updates Investors with Regulation FD Presentation

August 17, 2026 | tipranks.com

Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update

August 13, 2026 | finance.yahoo.com

Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update

August 13, 2026 | globenewswire.com

Vivani Medical Completes Enrollment, Dosing in Phase 1 SLIM-1 Trial

August 6, 2026 | finance.yahoo.com

ClearOne (CLRO) stock soars over 98% after hours: Here's what you need to know

August 6, 2026 | msn.com

Vivani Medical Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic ...

August 6, 2026 | finance.yahoo.com

Vivani Completes Enrollment in SLIM-1 Semaglutide Implant Trial

August 6, 2026 | tipranks.com

Vivani Medical to Present at the Emerging Growth Conference on July 15, 2026

July 14, 2026 | globenewswire.com

Next Frontier In Weight Loss? New Implant Looks To Lock In GLP-1 Results

July 14, 2026 | msn.com

The next GLP-1 bet? Implant draws Novo interest

July 13, 2026 | beckershospitalreview.comB

Vivani Medical

July 13, 2026 | fool.com

Weight-loss implant could one day replace Ozempic injections

July 12, 2026 | msn.com

Novo Nordisk (CPSE:NOVO B) Could Be 13% Overvalued Following Its Vivani Deal

July 9, 2026 | finance.yahoo.com

Vivani Medical signs agreement with Novo Nordisk to evaluate NPM-139

July 9, 2026 | pharmabiz.comP

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ABVC, RFL, VANI, and AARD Company Descriptions

Aardvark Therapeutics NASDAQ:AARD

$5.38 -0.15 (-2.71%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$5.38 +0.00 (+0.09%)

As of 09/18/2026 07:30 PM Eastern

Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.

ABVC BioPharma NASDAQ:ABVC

$1.16 +0.01 (+0.87%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$1.16 0.00 (-0.43%)

As of 09/18/2026 07:30 PM Eastern

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.

Rafael NYSE:RFL

$2.06 0.00 (-0.15%)

Closing price 09/18/2026 03:59 PM Eastern

Extended Trading

$2.06 0.00 (-0.10%)

As of 09/18/2026 07:30 PM Eastern

Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1B clinical studies; Folate-targeted Promitil (Promi-Fol) which is aimed at local treatment (intravesical) of superficial bladder cancer; and Promi-Dox, a highly potent dual drug liposome with MLP and doxorubicin targeting a potential basket of tumors. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrumentation. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.

Vivani Medical NASDAQ:VANI

$1.19 -0.02 (-1.65%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$1.20 +0.01 (+0.42%)

As of 09/18/2026 07:41 PM Eastern

Vivani Medical, Inc., a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals. The company is headquartered in Emeryville, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ABVC, RFL, VANI, and AARD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ABVC, RFL, VANI, and AARD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ABVC, RFL, VANI, and AARD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ABVC, RFL, VANI, and AARD Company Descriptions

Aardvark Therapeutics NASDAQ:AARD

ABVC BioPharma NASDAQ:ABVC

Rafael NYSE:RFL

Vivani Medical NASDAQ:VANI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ABVC, RFL, VANI, and AARD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ABVC, RFL, VANI, and AARD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ABVC, RFL, VANI, and AARD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ABVC, RFL, VANI, and AARD Company Descriptions

Aardvark Therapeutics NASDAQ:AARD

ABVC BioPharma NASDAQ:ABVC

Rafael NYSE:RFL

Vivani Medical NASDAQ:VANI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools